Amicus Therapeutics Announces Preliminary Unaudited Revenue Results of Galafold for the Fourth Quarter and Year 2019
January 09, 2020 at 12:05 pm
Share
Amicus Therapeutics announced preliminary 2019 revenue and Galafold (migalastat) commercial updates. Global revenue for Galafold in full-year 2019 was approximately $181 million (preliminary and unaudited) representing a year-over-year increase of 99% from total revenue of $91 million in 2018 and exceeded the Company’s updated 2019 guidance of $170 million to $180 million. Full-year revenue was negatively impacted by approximately $5 million in foreign currency headwinds.
Fourth quarter Galafold revenue was approximately $54 million (preliminary and unaudited).
Amicus Therapeutics, Inc. is a biotechnology company, which is focused on discovering, developing, and delivering novel medicines for rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a novel treatment designed to improve uptake of active enzyme into key disease relevant tissues for adults living with late-onset Pompe disease. As an orally administered monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A (alpha-Gal A) enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice (GLP) cell-based amenability assay. Pombiliti + Opfolda consists of a uniquely engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance lysosomal uptake, administered in combination with miglustat that functions as an enzyme stabilizer.
AMICUS THERAPEUTICS, INC. 
